Resultados de procura - Mojca Jongen‐Lavrencic

Limitar resultados
  1. 1
    The versatile nature of miR-9/9* in human cancer

    The versatile nature of miR-9/9* in human cancer por Katarzyna Nowek, Erik A.C. Wiemer, Mojca Jongen‐Lavrencic

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013

    Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013 por Avinash G. Dinmohamed, Mirian Brink, Otto Visser, Mojca Jongen‐Lavrencic

    Publicado 2016
    Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  3. 3
    Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival

    Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival por Avinash G. Dinmohamed, Anikó Szabó, Marianne van der Mark, Otto Visser, Pieter Sonneveld, Jan J. Cornelissen, Mojca Jongen‐Lavrencic, Anita W. Rijneveld

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation

    The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation por Su Jung Song, Keisuke Ito, Ugo Ala, Lev M. Kats, Kaitlyn A. Webster, Su Ming Sun, Mojca Jongen‐Lavrencic, Katia Manova‐Todorova, Julie Teruya‐Feldstein, David Avigan, Ruud Delwel, Pier Paolo Pandolfi

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia

    Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia por Steffen Hirsch, Tamara J. Blätte, Sarah Grasedieck, Sibylle Cocciardi, A. MAUREEN ROUHI, Mojca Jongen‐Lavrencic, Peter Paschka, Jan Krönke, Verena I. Gaidzik, Hartmut Döhner, Richard F. Schlenk, Florian Kuchenbauer, Konstanze Döhner, Anna Dolnik, Lars Bullinger

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP

    Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP por Stefan Hatzl, Olivia Geiger, Maja Kim Kuepper, Veronica Caraffini, Till Seime, Tobias Furlan, Erika Nussbaumer, Rotraud Wieser, Martin Pichler, Marcel Scheideler, Katarzyna Nowek, Mojca Jongen‐Lavrencic, Franz Quehenberger, Albert Wölfler, Jakob Troppmair, Heinz Sill, Armin Zebisch

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

    CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping por A.E. Bras, Valérie de Haas, Arthur van Stigt, Mojca Jongen‐Lavrencic, H. Berna Beverloo, Jeroen G. te Marvelde, C. Michel Zwaan, Jacques J. M. van Dongen, Jeanette H.W. Leusen, Vincent H. J. van der Velden

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

    Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia por Bob Löwenberg, Petra Muus, Gert J. Ossenkoppele, Philippe Rousselot, Jean‐Yves Cahn, Norbert Ifrah, Giovanni Martinelli, Sergio Amadori, Ellin Berman, Pieter Sonneveld, Mojca Jongen‐Lavrencic, Sophie Rigaudeau, Paul K. Stockman, Alison Goudie, Stefan Faderl, Elias Jabbour, Hagop M. Kantarjian

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

    Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia por Tim Grob, Mathijs A. Sanders, Christian M. Vonk, F. G. Kavelaars, Melissa Rijken, Diana Hanekamp, Patrycja Gradowska, Jacqueline Cloos, Yngvar Fløisand, Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Violaine Havelange, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

    MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice por Annemarie Meenhuis, Peter A. van Veelen, Hans de Looper, Nicole van Boxtel, Iris J. van den Berge, Su Ming Sun, Erdogan Taskesen, Patrick Stern, Arnoud H. de Ru, Arjan J. van Adrichem, Jeroen Demmers, Mojca Jongen‐Lavrencic, Bob Löwenberg, Ivo P. Touw, Phillip A. Sharp, Stefan J. Erkeland

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

    High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia por Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten, Harry C. Schouten, Carlos Graux, Augustin Ferrant, Pieter Sonneveld, Johan Maertens, Mojca Jongen‐Lavrencic, Marie von Lilienfeld‐Toal, Bart J. Biemond, Edo Vellenga, Marinus van Marwijk Kooy, Leo F. Verdonck, Joachim Beck, Hartmut Döhner, Aloïs Gratwohl, Thomas Pabst, Gregor Verhoef

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

    Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study por Bob Löwenberg, Joachim Beck, Carlos Graux, Wim van Putten, Harry C. Schouten, Leo F. Verdonck, Augustin Ferrant, Pieter Sonneveld, Mojca Jongen‐Lavrencic, Marie von Lilienfeld‐Toal, Bart J. Biemond, Edo Vellenga, Dimitri Breems, Hilde de Muijnck, Ron Schaafsma, Gregor Verhoef, Hartmut Döhner, Aloïs Gratwohl, Thomas Pabst, Gert J. Ossenkoppele, Johan Maertens

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    The non-coding RNA landscape of human hematopoiesis and leukemia

    The non-coding RNA landscape of human hematopoiesis and leukemia por Adrian Schwarzer, Stephan Emmrich, Franziska Schmidt, Dominik Beck, Michelle Ng, Christina Reimer, Felix F. Adams, Sarah Grasedieck, Damian Witte, Sebastian Käbler, Jason W.H. Wong, Anushi Shah, Yizhou Huang, Razan Jammal, Aliaksandra Maroz, Mojca Jongen‐Lavrencic, Axel Schambach, Florian Kuchenbauer, John E. Pimanda, Dirk Reinhardt, Dirk Heckl, Jan‐Henning Klusmann

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

    Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients por Gerwin Huls, Dana Chiţu, Violaine Havelange, Mojca Jongen‐Lavrencic, Arjan A. van de Loosdrecht, Bart J. Biemond, Harm Sinnige, Beata Hodossy, Carlos Graux, Rien van Marwijk Kooy, Okke de Weerdt, Dimitri Breems, Saskia K. Klein, Jürgen Kuball, Dries Deeren, Wim Terpstra, Marie‐Christiane Vekemans, Gert J. Ossenkoppele, Edo Vellenga, Bob Löwenberg

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia

    Molecular Minimal Residual Disease in Acute Myeloid Leukemia por Mojca Jongen‐Lavrencic, Tim Grob, Diana Hanekamp, François G. Kavelaars, Adil Al Hinai, Annelieke Zeilemaker, Claudia Erpelinck-Verschueren, Patrycja Gradowska, Rosa Meijer, Jacqueline Cloos, Bart J. Biemond, Carlos Graux, Marinus van Marwijk Kooy, Markus G. Manz, Thomas Pabst, Jakob Passweg, Violaine Havelange, Gert J. Ossenkoppele, Mathijs A. Sanders, Gerrit Jan Schuurhuis, Bob Löwenberg, Peter J.M. Valk

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome

    Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome por Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja Gradowska, Bart J. Biemond, Dimitri Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

    Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON)... por Gert J. Ossenkoppele, Georg Stüssi, Johan Maertens, Kees van Montfort, Bart J. Biemond, Dimitri Breems, A. Ferrant, Carlos Graux, Georgine E. de Greef, Constantijn J.M. Halkes, Mels Hoogendoorn, Rene Hollestein, Mojca Jongen‐Lavrencic, Mark Levin, Arjan A. van de Loosdrecht, Marinus van Marwijk Kooij, Yvette van Norden, Thomas Pabst, Harry C. Schouten, Edo Vellenga, Gregor Verhoef, Okke de Weerdt, P. Wijermans, Jakob Passweg, Bob Löwenberg

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

    Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years por Jan J. Cornelissen, Jurjen Versluis, Jakob Passweg, Wim L.J. van Putten, Markus G. Manz, Johan Maertens, H. Berna Beverloo, Peter J.M. Valk, Marinus van Marwijk Kooy, P. Wijermans, Martyn Ronald Schaafsma, Bart J. Biemond, MC Vekemans, Dimitri Breems, Leo F. Verdonck, Martin F. Fey, Mojca Jongen‐Lavrencic, Jeroen J.W.M. Janssen, Gerwin Huls, Jürgen Kuball, Thomas Pabst, Carlos Graux, Harry C. Schouten, Aloïs Gratwohl, Edo Vellenga, G.J. Ossenkoppele, Bob Löwenberg

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

    Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML por Bob Löwenberg, Thomas Pabst, Johan Maertens, Yvette van Norden, Bart J. Biemond, Harry C. Schouten, Olivier Spertini, Edo Vellenga, Carlos Graux, Violaine Havelange, Georgine E. de Greef, Okke de Weerdt, Marie-Cecile J. C. Legdeur, Juergen Kuball, Marinus van Marwijk Kooy, Bjørn Tore Gjertsen, Mojca Jongen‐Lavrencic, Arjan A. van de Loosdrecht, Daniëlle van Lammeren‐Venema, Beata Hodossy, Dimitri Breems, Yves Chalandon, Jakob Passweg, Peter J.M. Valk, Markus G. Manz, Gert J. Ossenkoppele

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

    Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study por Jeffrey E. Lancet, Farhad Ravandi, Pau Montesinos, Jacqueline C. Barrientos, Talha Badar, Adrián Alegre, Asad Bashey, Juan Miguel Bergua Burgués, Lorenzo Brunetti, Emily Curran, David C. Christian de Leeuw, Enrico Derenzini, Geert A. Huls, Jeroen J.W.M. Janssen, Deepa Jeyakumar, Mojca Jongen‐Lavrencic, Ashwin Kishtagari, María‐Victoria Mateos, Daniel Morillo, Alessandro Rambaldi, Aaron S. Rosenberg, Gary J. Schiller, Uzma Ahmed, Alexandru Cacovean, Stephan W. Morris, Courtney A. Follit, Brian Munneke, Ganesh Waghmare, Clarissa Mandap, Mona Vimal, Thomas W. Butler, Hetty E. Carraway

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: